Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer.

Green tea catechins (GTCs) exert chemopreventive effects in many cancer models. Several studies implicate the DNA synthesis marker minichromosome maintenance protein 7 (MCM7) in prostate cancer progression, growth and invasion; representing a novel therapeutic target. In this study, we investigated the effect of GTCs on MCM7 expression in the transgenic adenocarcinoma mouse prostate model (TRAMP). DNA microarray, immunohistochemistry and western blot analysis showed that GTCs significantly suppressed MCM7 in the TRAMP mice treated with GTCs. Our study indicates that the cellular DNA replication factor MCM7 is involved in prostate cancer (CaP) and MCM7 gene expression was reduced by GTCs. Together, these results suggest a possible role of GTCs in CaP chemoprevention in which MCM7 plays a critical role

Prognostic role of clusterin in resected adenocarcinomas of the lung

Rationale Clusterin expression may change in various human malignancies, including lung cancer. Patients with resectable non-small cell lung cancer (NSCLC), including adenocarcinoma, have a poor prognosis, with a relapse rate of 30\u201350% within 5 years. Nuclear factor kB (Nf-kB) is an intracellular protein involved in the initiation and progression of several human cancers, including the lung. Objectives We investigate the role of clusterin and Nf-kB expression in predicting the prognosis of patients with early-stage surgically resected adenocarcinoma of the lung. Findings The level of clusterin gradually decreased from well-differentiated to poorly differentiated adenocarcinomas. Clusterin expression was significantly higher in patients with low-grade adenocarcinoma, in early-stage disease and in women. Clusterin expression was inversely related to relapse and survival in both univariate and multivariate analyses. Finally, we observed an inverse correlation between Nf-kB and clusterin. Conclusions Clusterin expression represents an independent prognostic factor in surgically resected lung adenocarcinoma and was proven to be a useful biomarker for fewer relapses and longer survival in patients in the early stage of disease. The inverse correlation between Nf-kB and clusterin expression confirm the previously reported role of clusterin as potent down regulator of Nf-kB

A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR

Prostate cancer (CaP) is one of the most relevant causes of cancer death in Western Countries. Although detection of CaP at early curable stage is highly desirable, actual screening methods present limitations and new molecular approaches are needed. Gene expression analysis increases our knowledge about the biology of CaP and may render novel molecular tools, but the identification of accurate biomarkers for reliable molecular diagnosis is a real challenge. We describe here the diagnostic power of a novel 8-genes signature: ornithine decarboxylase (ODC), ornithine decarboxylase antizyme (OAZ), adenosylmethionine decarboxylase (AdoMetDC), spermidine/spermine N(1)-acetyltransferase (SSAT), histone H3 (H3), growth arrest specific gene (GAS1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Clusterin (CLU) in tumour detection/classification of human CaP. METHODOLOGY/PRINCIPAL FINDINGS: The 8-gene signature was detected by retrotranscription real-time quantitative PCR (RT-qPCR) in frozen prostate surgical specimens obtained from 41 patients diagnosed with CaP and recommended to undergo radical prostatectomy (RP). No therapy was given to patients at any time before RP. The bio-bank used for the study consisted of 66 specimens: 44 were benign-CaP paired from the same patient. Thirty-five were classified as benign and 31 as CaP after final pathological examination. Only molecular data were used for classification of specimens. The Nearest Neighbour (NN) classifier was used in order to discriminate CaP from benign tissue. Validation of final results was obtained with 10-fold cross-validation procedure. CaP versus benign specimens were discriminated with (80+/-5)% accuracy, (81+/-6)% sensitivity and (78+/-7)% specificity. The method also correctly classified 71% of patients with Gleason score<7 versus > or =7, an important predictor of final outcome. CONCLUSIONS/SIGNIFICANCE: The method showed high sensitivity in a collection of specimens in which a significant portion of the total (13/31, equal to 42%) was considered CaP on the basis of having less than 15% of cancer cells. This result supports the notion of the "cancer field effect", in which transformed cells extend beyond morphologically evident tumour. The molecular diagnosis method here described is objective and less subjected to human error. Although further confirmations are needed, this method poses the potential to enhance conventional diagnosis

Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer

Green tea catechins (GTCs) exert chemopreventive effects in many cancer models. Several studies implicate the DNA synthesis marker minichromosome maintenance protein 7 (MCM7) in prostate cancer progression, growth and invasion; representing a novel therapeutic target. In this study, we investigated the effect of GTCs on MCM7 expression in the transgenic adenocarcinoma mouse prostate model (TRAMP). DNA microarray, immunohistochemistry and Western blot analysis showed that GTCs significantly suppressed MCM7 in the TRAMP mice treated with GTCs. Our study indicates that the cellular DNA replication factor MCM7 is involved in prostate cancer (CaP) and MCM7 gene expression was reduced by GTCs. Together, these results suggest a possible role of GTCs in CaP chemoprevention in which MCM7 plays a critical role

RESPONSES OF LIVER-ENZYMES TO CADMIUM ADMINISTRATION IN THE GOLDFISH (CARASSIUS-AURATUS) AT DIFFERENT TIMES OF THE YEAR

The activity of goldfish liver ornithine and adenosylmethionine decarboxylase increased upon cadmium chloride injection in April and November. Liver metal concentration increased after the injection and hepatic metallothionein was induced at all times independently of the responses of the two enzymes

Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment

Finasteride is a well-known inhibitor of the prostatic enzyme 5 alpha -reductase type 2 which prevents conversion of testosterone into 5 alpha -dihydrotestosterone, the active intraprostatic androgen, which causes prostate involution through a combination of cell atrophy and cell death. The drug is widely used to improve symptoms of benign prostatic hyperplasia in man. Clusterin, a glycoprotein which is generally up-regulated under conditions inducing cell atrophy or organ involution, is produced at a high level in the regressing rat ventral prostate following androgen ablation. According to several authors, clusterin does not respond to finasteride treatment, suggesting a different action of testosterone and 5 alpha -dihydrotestosterone. We show here that, under our conditions, finasteride was capable of inducing production of both clusterin mRNA and protein in the rat ventral prostate. In fact, by using different and converging techniques, such as Northern hybridization, in situ hybridization histochemistry and immunohistochemistry, we were able to show a strong induction of the clusterin gene in the epithelial cell population of the gland. The response to finasteride, which was similar to that seen with castration, occurred with a delay of a few days. In situ and immunohistochemistry experiments indicated that both orchidectomy and finasteride administration resulted in increased transition of the epithelial cells from the columnar to the cuboidal (atrophic) shape, and this was accompanied by an increased intensity of the signal for clusterin. Thus, it appears that induction of clusterin is part of the molecular process leading to prostate involution caused by either orchidectomy or finasteride administration

Gene expression analysis in combination with clinical parameters is effective in predicting relapse after radical prostatectomy

Early prediction of tumour recurrence at the time of radical prostatectomy (RRP) would certainly be of great importance for deciding possible adjuvant therapy in patients with prostate cancer (CaP). Clinical and pathological parameters can correctly predict recurrence in no more than 70% of cases. Gene expression analysis is a powerful method for studying prostate cancer biology. Recent studies have been directed to identifying new genes implicated in CaP initiation and progression and establishing novel methods for validation of differentially expressed genes in cancers at moderate and high risk of progression. The objectives of this study were to evaluate whether (a) the assessment of the expression profiles of a set of genes, directly or indirectly related to cell proliferation state or apoptic activity, can correctly predict relapse of CaP at the time of RRP and (b) a combination of gene expression profile data with standard clinical-pathological parameters can further enhance the prediction potential. The study was conducted on 355 patients with localised CaP, undergoing RRP, but only 23 pairs of prostate specimens (tumour and matched benign tissues of the same gland) were eligible for the analysis. Age, familiarity, PSA, prostate volume, stage and grade were evaluated for prognosis as clinical and pathological parameters. The level of expression of a panel of 8 genes related to polyamine metabolism, cell proliferation and apoptosis were measured in tumours and matched normal tissues. After undergoing RRP, patients were regularly followed up at our center with physical examination (PE) and PSA measurement. After a mean time of 62.3 months 13 out of 23 patients (56.5%) did not recur (Group 1), while the remaining 10 patients (43.5%) had a relapse (Group 2). When patients were classified according to clinical-pathological parameters, the overall correct prediction of recurrence was 87% (Group 1 = 100%, Group 2 = 70%). When patients were classified according to gene profiling alone the overall correct prediction was 82.6% (Group 1 = 84.6%, Group 2 = 80%). When combining gene profiling and clinical-pathological parameters a 95.7% prediction rate was obtained (Group 1 = 100%, Group 2 = 90%)